Grifols

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Subsidiary, Public

Established: 1940-01-01

Employees: 23.7K

Market Cap: $6.8B

Website: http://www.grifols.com

Introduction: Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Clinical Trials

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

Phase 2

Completed

Conditions: Acute Peripheral Arterial Occlusion

Interventions: Biological: Plasmin
Biological: Plasminogen Activator
Other: Placebo

First Posted Date: 2010-10-18

Last Posted Date: 2017-01-16

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 174

Registration Number: NCT01222117

Locations: 🇺🇸
Kaleida Health System, Buffalo, New York, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇧🇪
Ziekenhuis Oost Limburg, Campus St. Jan, Genk, Limburg, Belgium

and more 36 locations

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Phase 2

Completed

Conditions: Emphysema
Alpha 1-antitrypsin Deficiency (AATD)

Interventions: Biological: Prolastin-C, 60 mg/kg
Biological: Prolastin-C, 120 mg/kg

First Posted Date: 2010-10-01

Last Posted Date: 2013-05-20

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 30

Registration Number: NCT01213043

Locations: 🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Temple University Hosptial/Temple Lung Center, Philadelphia, Pennsylvania, United States

and more 2 locations

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Phase 1

Completed

Conditions: Acute Ischemic Stroke

Interventions: Biological: Plasmin (Human)

First Posted Date: 2009-11-17

Last Posted Date: 2015-10-21

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 40

Registration Number: NCT01014975

Locations: 🇷🇸
Clinical Center Niš, Center of Radiology, Niš, Serbia
🇷🇸
Clinical Center of Vojvodina, Center for Radiology, Novi Sad, Serbia
🇦🇹
O.O. Landes-Nervenklinik Wagner-Jauregg, Linz, Upper Austria, Austria

and more 20 locations

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Alpha1-Proteinase Inhibitor (Human)

First Posted Date: 2007-06-15

Last Posted Date: 2014-08-21

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 72

Registration Number: NCT00486837

Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels

Phase 4

Terminated

Conditions: Tetanus

Interventions: Drug: Tetanus Immune Globulin (Human)
Biological: Diphtheria-Tetanus Toxoids Adsorbed

First Posted Date: 2007-02-21

Last Posted Date: 2016-01-20

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 6

Registration Number: NCT00437671

Locations: 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

Phase 1

Completed

Conditions: Arterial Occlusive Diseases

Interventions: Biological: Plasmin (Human) 125 mg
Biological: Plasmin (Human) 50 mg
Biological: Plasmin (Human) 100 mg
Biological: Plasmin (Human) 150 mg
Biological: Plasmin (Human) 25 mg
Biological: Plasmin (Human) 75 mg
Biological: Plasmin (Human) 175 mg

First Posted Date: 2007-01-04

Last Posted Date: 2016-10-31

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 83

Registration Number: NCT00418483

Locations: 🇺🇸
Jobst Vascular Institute, Toledo, Ohio, United States

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Phase 2

Completed

Conditions: Immunologic Deficiency Syndrome

Interventions: Biological: Immune Globulin Intravenous (Human)

First Posted Date: 2006-10-18

Last Posted Date: 2015-04-20

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 35

Registration Number: NCT00389324

Locations: 🇨🇦
McGill University - Montreal General Hospital, Montreal, Quebec, Canada
🇨🇦
Dr. Donald F. Stark, Inc, Vancouver, British Columbia, Canada
🇺🇸
University of California, Irvine, Irvine, California, United States

and more 5 locations

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

Phase 3

Completed

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: alpha-1 proteinase inhibitor (human)

First Posted Date: 2006-03-10

Last Posted Date: 2014-08-19

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 38

Registration Number: NCT00301366

Locations: 🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇬🇧
University of Cambridge - Cambridge Institute for Medical Research, Cambridge, England, United Kingdom

and more 7 locations

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

Phase 3

Completed

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: Alpha-1 MP
Drug: alpha-1 proteinase inhibitor (human)

First Posted Date: 2006-02-22

Last Posted Date: 2014-09-09

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 24

Registration Number: NCT00295061

Locations: 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
🇺🇸
St Lukes-Roosevelt Hospital Center, New York, New York, New York, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 5 locations

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Phase 2

Completed

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: Alpha1-Proteinase Inhibitor (Human)
Drug: Albumin (Human) 20%, United States Pharmacopeia (USP)

First Posted Date: 2005-12-09

Last Posted Date: 2014-08-21

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 77

Registration Number: NCT00263887

Locations: 🇩🇰
Gentofte Hospital Department of Respiratory Medicine, Hellerup, Denmark
🇸🇪
Department of Pulmonary Medicine, Malmö University Hospital, Malmö, Sweden
🇬🇧
Queen Elizabeth Hospital, Birmingham, England, United Kingdom

Home Terms & Conditions Privacy Policy